Tech Center 1600 • Art Units: 1626
This examiner grants 49% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18034520 | Modulators of Orphan Nuclear Receptors for Treating Pancreatitis, Glioblastoma, Sarcopenia and Stroke | Non-Final OA | Emory University |
| 18578617 | Compounds for Modulating Epithelial 15-(S)-Lipoxygenase-2 and Methods of Use for Same | Non-Final OA | The Regents of the University of California |
| 19329060 | VERY LONG CHAIN FATTY ACIDS FOR TREATMENT AND ALLEVIATION OF DISEASES | Non-Final OA | EPAX NORWAY AS |
| 17625023 | METHODS OF USING MODIFIED CYTOTOXINS TO TREAT CANCER | Non-Final OA | NORTHWESTERN UNIVERSITY |
| 17628717 | RECOVERY METHOD AND RECOVERY APPARATUS OF NITRILE-BASED MONOMER | Non-Final OA | LG CHEM, LTD. |
| 17606720 | CF3-, OCF3-, SCF3-, and SF5-Containing Antibacterial Agents | Non-Final OA | Purdue Research Foundation |
| 17610130 | METHODS FOR TREATING DISORDERS ASSOCIATED WITH SLEEP SPINDLE DEFICITS | Non-Final OA | Massachusetts Institute of Technology |
| 18411753 | METHODS FOR PREVENTING OR SLOWING THE PROGRESSION OF COGNITIVE DECLINE OR IMPAIRMENT IN SUBJECTS | Non-Final OA | The Johns Hopkins University |
| 18004314 | COMBINATIONS OF CANCER THERAPEUTICS | Final Rejection | Merck Patent GmbH |
| 17595451 | DIETARY BUTYRATE AND ITS USES | Non-Final OA | SOCIETE DES PRODUITS NESTLE S.A. |
| 18527638 | TREATMENT OF ACUTE ANXIETY WITH AN ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATOR | Non-Final OA | Vanda Pharmaceuticals Inc. |
| 17206835 | ORGANIC ELECTROLUMINESCENT COMPOUND, ORGANIC ELECTROLUMINESCENT MATERIAL COMPRISING THE SAME, AND ORGANIC ELECTROLUMINESCENT DEVICE | Non-Final OA | ROHM AND HAAS ELECTRONIC MATERIALS KOREA LTD. |
| 18681685 | A PROCESS FOR PREPARING BENZOXAZINONE COMPOUNDS | Non-Final OA | Tagros Chemicals India Pvt Ltd |
| 18572412 | SHP2 AND CDK4/6 INHIBITORS COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | Non-Final OA | Erasca, Inc. |
| 18557538 | PHARMACEUTICAL COMPOSITION COMPRISING GPR40 AGONIST AND SGLT-2 INHIBITOR | Non-Final OA | ILDONG PHARMACEUTICAL CO., LTD. |
| 18039959 | HYDROXAMATE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Non-Final OA | SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. |
| 17631773 | COMPOSITION COMPRISING STEROL DERIVATIVES FOR USE IN THE TREATMENT OF A NEURONAL PATHOLOGY RELATED TO HYPOXIA, HYPOGLYCEMIA AND/OR HYPERGLYCEMIA | Final Rejection | DENDROGENIX |
| 17917842 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | Final Rejection | REMIX THERAPEUTICS INC. |
| 18245636 | IMPROVED PROCESS FOR PREPARATION OF ANTHRANILAMIDES | Final Rejection | GSP CROP SCIENCE PRIVATE LIMITED |
| 18026034 | NOVEL COPI/ARF1-LIPOLYSIS PATHWAY INHIBITOR AND COMPOUND FOR ERADICATING CANCER STEM CELLS AND INDUCING DAMP-MEDIATED ANTI-TUMOR IMMUNE RESPONSE | Non-Final OA | GREATER BAY AREA INSTITUTE OF PRECISION MEDICINE (GUANGZHOU) |
| 18020242 | COMPOUNDS AS C5AR INHIBITORS | Non-Final OA | Kira Pharmaceuticals (Suzhou) Ltd. |
| 18016006 | METHODS OF REDUCING INCIDENCE OR RISK OF CEREBRAL FOLATE DEFICIENCY | Non-Final OA | LAM, Dominic Man-Kit |
| 17437087 | USE OF VITAMIN K IN COMBINATION WITH ANTICOAGULANTS | Non-Final OA | KAYDENCE PHARMA AS |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy